0
0
No products in the cart.
This priority review is coming after an Advisory Committee voted 6-4 against it. However, the FDA does what they want after taking the Ad Coms suggestions into account. If they read the data differently, or determine there is special need for the drug on trial, they could opt to do something other than a rejection.